BVS
Bioventus Inc.Company Information
- Company Name
- Bioventus Inc.
- CIK
- CIK0001665988
- Category
- Accelerated filer<br>Emerging growth company
- Ticker: Exchange
- BVS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- BVS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-19
- Last sale
- 2026-03-11
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 56,929
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 53,665,018
- Shares outstanding
- 67,869,148
- Ownership
- 79.07%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -9.31%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 29 | 36 | 51 | 42 | 33 | 23 | 42 | 43 | 32 | 25 | 37 | 27 | ||||||
| Accounts Receivable Net Current | 138 | 121 | 128 | 130 | 132 | 118 | 127 | 122 | 137 | 126 | 123 | 113 | ||||||
| Inventory Net | 80 | 83 | 82 | 96 | 96 | 94 | 92 | 90 | 88 | 97 | 91 | 98 | ||||||
| Prepaid Expense And Other Assets Current | 10 | 10 | 11 | 12 | 13 | 14 | 14 | 17 | 24 | 18 | 17 | 12 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | - | - | 27 | 28 | - | - | - | ||||||
| Assets Current | 258 | 250 | 273 | 281 | 275 | 249 | 276 | 299 | 309 | 266 | 268 | 249 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 21 | 21 | 22 | 23 | 25 | 26 | 27 | 29 | 32 | 35 | 37 | 40 | ||||||
| Goodwill | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Intangible Assets Net Excluding Goodwill | 351 | 360 | 368 | 377 | 387 | 396 | 405 | 415 | 425 | 471 | 482 | 493 | ||||||
| Operating Lease Right Of Use Asset | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 10 | 10 | 12 | 13 | 14 | ||||||
| Deferred Income Tax Assets Net | 29 | 6 | - | 5 | 5 | 5 | - | 7 | 7 | - | - | - | ||||||
| Long Term Investments | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 7 | ||||||
| Assets | 673 | 651 | 684 | 702 | 707 | 691 | 728 | 769 | 792 | 794 | 811 | 811 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 20 | 24 | 11 | 27 | 24 | 19 | 24 | 17 | 24 | 19 | 23 | 18 | ||||||
| Accrued Liabilities Current | 109 | 101 | 130 | 119 | 114 | 103 | 136 | 129 | 140 | 114 | 120 | 119 | ||||||
| Long Term Debt Current | 19 | 19 | 15 | 11 | 43 | 37 | 27 | 39 | 39 | 36 | 28 | 20 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | 0 | 0 | 0 | 11 | 20 | 19 | 19 | - | 0 | - | ||||||
| Other Liabilities Current | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | ||||||
| Liabilities Current | 152 | 148 | 160 | 162 | 186 | 175 | 210 | 211 | 231 | 173 | 175 | 161 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Long Term Debt Noncurrent | 230 | 253 | 279 | 311 | 298 | 309 | 308 | 345 | 345 | 355 | 367 | 375 | ||||||
| Deferred Income Tax Liabilities Net | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 18 | 18 | 18 | ||||||
| Other Liabilities Noncurrent | 13 | 14 | 15 | 20 | 21 | 22 | 23 | 26 | 27 | 28 | 28 | 31 | ||||||
| Liabilities | 396 | 416 | 455 | 494 | 505 | 506 | 542 | 583 | 603 | 577 | 590 | 585 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Additional Paid In Capital | 528 | 523 | 521 | 518 | 515 | 510 | 508 | 503 | 501 | 497 | 494 | 492 | ||||||
| Retained Earnings Accumulated Deficit | -298 | -332 | -335 | -350 | -353 | -360 | -358 | -355 | -350 | -326 | -322 | -315 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -2 | -2 | -2 | -1 | -2 | -3 | 0 | -0 | 0 | 1 | 0 | ||||||
| Stockholders Equity | 228 | 234 | 184 | 207 | 201 | 185 | 186 | 187 | 151 | 217 | 221 | 226 | ||||||
| Minority Interest | 49 | 45 | 44 | 41 | 40 | 37 | 38 | 38 | 38 | 46 | 48 | 49 | ||||||
| Liabilities And Stockholders Equity | 673 | 651 | 684 | 702 | 707 | 691 | 728 | 769 | 792 | 794 | 811 | 811 | ||||||
| Common Class A | 1 | 68 | 0 | 0 | 1 | 66 | 0 | 0 | 1 | 64 | 0 | 0 | ||||||
| Common Class B | 0 | 16 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 16 | 16 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBioventus Inc. (BVS) — SEC Financial Statements & Analysis
Bioventus Inc. (BVS) is a surgical & medical instruments & apparatus company, incorporated in DE. Bioventus Inc. trades on Nasdaq as: BVS. Bioventus Inc. (BVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Bioventus Inc. carries a market cap of $640.68M, a P/E ratio of 12.45x, a P/B ratio of 2.81x, a P/S ratio of 1.10x, an enterprise value of $859.68M, and an EV/EBITDA multiple of 8.25x. On profitability, it posts a gross margin of 68.65%, an operating margin of 10.02%, a net margin of 8.85%, a Return on Equity (ROE) of 23.97%, a Return on Assets (ROA) of 7.46%, and a Return on Invested Capital (ROIC) of 11.90%. Per share, it reports EPS of $0.76, diluted EPS of $0.73, free cash flow per share of $1.39, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 3.14% year-over-year, net income growth of -434.29% year-over-year, and EPS growth of -427.55% year-over-year. On the balance sheet, it maintains a current ratio of 1.69x, a quick ratio of 1.10x, working capital of $105.08M, a debt-to-equity ratio of 1.73x, a debt ratio of 0.59, an interest coverage ratio of 2.93x, free cash flow of $94.29M (TTM), and net debt of $219.00M. Figures sourced from SEC EDGAR.
- Market Cap
- $640.68M
- P/E TTM
- 12.45x
- EPS TTM
- $0.76
- P/B TTM
- 2.81x
- ROE TTM
- 23.97%
- ROA TTM
- 7.46%
- Debt To Equity
- 1.73x
- Free Cash Flow TTM
- $94.29M
- Net Revenue TTM Growth 1Y
- 3.14%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Bioventus Inc. in?
Bioventus Inc. (BVS) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does BVS trade on?
Bioventus Inc. (BVS) trades on the Nasdaq.
Where is Bioventus Inc. incorporated?
Bioventus Inc. is incorporated in DE.
When was Bioventus Inc. (BVS)'s most recent SEC filing?
Bioventus Inc. (BVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is BVS's market cap?
Bioventus Inc. (BVS) has a market capitalization of $640.68M as of 2026-06-30.
What is BVS's P/E ratio?
Bioventus Inc. (BVS)'s trailing twelve month P/E ratio is 12.45x as of 2026-06-30.
What is BVS's EPS (earnings per share)?
Bioventus Inc. (BVS)'s trailing twelve month EPS is $0.76 as of 2026-06-30.
What is BVS's ROE (return on equity)?
Bioventus Inc. (BVS)'s trailing twelve month Return on Equity (ROE) is 23.97% as of 2026-06-30.
What is BVS's ROA (return on assets)?
Bioventus Inc. (BVS)'s trailing twelve month Return on Assets (ROA) is 7.46% as of 2026-06-30.
What is BVS's ROIC (return on invested capital)?
Bioventus Inc. (BVS)'s trailing twelve month Return on Invested Capital (ROIC) is 11.90% as of 2026-06-30.
What is BVS's EV/EBITDA?
Bioventus Inc. (BVS)'s trailing twelve month EV/EBITDA is 8.25x as of 2026-06-30.